BRAF and melanoma: The UK pathway of care for melanoma has changed considerably following the licensing and recommendation by the National Institute of Health and Care Excellence (NICE), between 2012–2014, of the immunotherapy ipilimumab, and the BRAF inhibitors vemurafenib and dabrafenib, which can be used in the 50% of patients whose melanoma harbours an activating mutation in the BRAF gene [8–11].